How to Buy Zevra Therapeutics Stock
Zevra Therapeutics Inc
Zevra Therapeutics, Inc. , a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
Zevra Therapeutics stock last closed at $6.87, down 3.92% from the previous day, and has increased 50.33% in one year. It has overperformed other stocks in the Biotechnology industry by 1.28 percentage points. Zevra Therapeutics stock is currently +63.57% from its 52-week low of $4.20, and -29.61% from its 52-week high of $9.76.
As of Apr 21, 2025, there are 54.12M ZVRA shares outstanding. The market capitalization of ZVRA is $371.78M. In the last 24 hours, 363,560 ZVRA shares were traded.
How to Buy Zevra Therapeutics Stock
Wondering how to invest in Zevra Therapeutics stock? Here's how.
- Choose where to buy Zevra Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Zevra Therapeutics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Choose your method of payment and add your info.
- Analyze Zevra Therapeutics stock: The Zevra Therapeutics ticker symbol is ZVRA. Is Zevra Therapeutics stock a good investment? Should you buy shares of ZVRA? How do ZVRA's underlying business fundamentals look? Do top analysts think Zevra Therapeutics is a good buy? Why has ZVRA's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if ZVRA is a good stock to buy).
- Place your ZVRA trade: Decide if you will purchase ZVRA shares at the current market price or use a limit order to purchase ZVRA stock at a particular price.
- Monitor your investment in ZVRA: Create a watchlist to watch your investment in Zevra Therapeutics stock.
Step 1: Choose where to buy Zevra Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy ZVRA shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked your brokerage, you need to fill out some personal details so you are able to invest in ZVRA stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on apps for stocks, you can securely and quickly fund your account:
Watch the tutorial below for more details transferring funds into your new brokerage account.
Step 4: Analyze Zevra Therapeutics stock
Once you have identified the best place to buy Zevra Therapeutics stock, it's absolutely critical to research their stock prior to investing, so you can comprehend the risk and opportunity.
Zevra Therapeutics quick stats
ZVRA Due Diligence Checks
WallStreetZen was built to help average investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on ZVRA's stock page.
Is ZVRA stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge ZVRA's true value.
Using relative valuations measures:
- ZVRA may be overvalued based on its P/B ratio of 9.37x, relative to Biotechnology industry P/B ratio of 4.04x
You can access additional valuation research on ZVRA's stock here.
ZVRA Financial Overview
Positive Health Checks:
- ZVRA has $69.50M in cash and short term investments. This is enough to cover its annual cash burn of $69.67M.
- There are more short-term assets than short-term liabilities on the ZVRA balance sheet.
- Total ZVRA debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
- ZVRA has cash burn of 69665000. It does not have sufficient cash and short-term investments to cover this.
- ZVRA has a relatively high debt to equity ratio of 3.49.
- ZVRA profit margin has gone down from -167.7% to -446.9% in the past year.
- There are more long-term liabilities than short-term assets on the ZVRA balance sheet.
Is it a good time to buy Zevra Therapeutics stock, according to analysts?
Out of 5 Equities analysts who research ZVRA, the consensus analyst rating on Zevra Therapeutics is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are saying on the Zevra Therapeutics stock forecast page.
Metrics for Advanced ZVRA Traders
ZVRA Revenue
Last year, ZVRA revenue was $23.61M. During the past 5 year, ZVRA's revenue has grown by 12.96% per year. This was slower than the Biotechnology industry average of 44.31%.
Dive into ZVRA's earnings and revenue performance here.
Are ZVRA executives and large shareholders buying or selling the stock?
In the past year, insiders at ZVRA have sold more shares than they have bought.
Corey Michael Watton, Director of ZVRA, was the latest ZVRA insider to buy. They bought $2,351.40 worth of ZVRA stock on Mar 28, 2025.
Get more info about who owns ZVRA shares here.
Does ZVRA provide a stable income stream?
No, Zevra Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about ZVRA
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your ZVRA trade
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually the easiest way to buy. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular price limit, place a limit order.
Press the Open button and eToro will place your order.
If you want more info about investing in stocks on eToro, click the how to video below:
Step 6: Monitor your investment in ZVRA
Now that you own some ZVRA stock, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of the latest news about your ZVRA stock.
ZVRA Feed
How to Buy Stock in Zevra Therapeutics
To reiterate, here are the 6 steps to buy stock in Zevra Therapeutics:
- Choose where to buy Zevra Therapeutics stock
- Create a brokerage account
- Put funds into your brokerage account
- Analyze Zevra Therapeutics stock
- Place your ZVRA trade
- Monitor your investment in ZVRA
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Zevra Therapeutics, click below.
More Stock Buying Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.